726 results on '"Asselain, Bernard"'
Search Results
2. Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial
3. Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.
4. Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial.
5. Quelles sont les pratiques en génétique des pédiatres onco-hématologues de la SFCE ? Une enquête du groupe socle éthique CONECT-AML
6. Comment améliorer la qualité méthodologique et l’adoption en routine des résultats des essais chirurgicaux ?
7. Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial
8. A Latent Time Distribution Model for the Analysis of Tumor Recurrence Data: Application to the Role of Age in Breast Cancer
9. Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada
10. Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study
11. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy
12. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)
13. Épidémiologie et spécificités socioculturelles de la femme jeune atteinte de cancer du sein
14. Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies
15. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review
16. Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns
17. #876 Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the chipor randomised phase III trial
18. #512 Real-World utilisation and clinical outcomes of patients with BRCA-mutated advanced ovarian cancer treated with olaparib in the first-line maintenance setting: 2-year clinical outcomes of the pan-European OVAL-1 study
19. Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)
20. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status
21. A Semiparametric Approach for the Two-Sample Comparison of Survival Times with Long-Term Survivors
22. Designs for Evaluating Precision Medicine Trials
23. A Distribution of Tumor Size at Detection: An Application to Breast Cancer Data
24. Supplementary Figures S1-S6 from Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection
25. Supplementary Data from Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors
26. Supplementary Video 2 from High PTP4A3 Phosphatase Expression Correlates with Metastatic Risk in Uveal Melanoma Patients
27. Supplementary Figure 1 from High PTP4A3 Phosphatase Expression Correlates with Metastatic Risk in Uveal Melanoma Patients
28. Supplementary Table 1 from High PTP4A3 Phosphatase Expression Correlates with Metastatic Risk in Uveal Melanoma Patients
29. Supplementary Table 1 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
30. Supplementary Video 3 from High PTP4A3 Phosphatase Expression Correlates with Metastatic Risk in Uveal Melanoma Patients
31. 6 supplementary figures from Chromatin Assembly Factor-1, a Marker of Clinical Value to Distinguish Quiescent from Proliferating Cells
32. Legends to supplementary figures from Chromatin Assembly Factor-1, a Marker of Clinical Value to Distinguish Quiescent from Proliferating Cells
33. Supplementary Figure 2 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
34. Supplementary Video 1 from High PTP4A3 Phosphatase Expression Correlates with Metastatic Risk in Uveal Melanoma Patients
35. Supplementary Figure 4 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
36. Supplementary Figure 3 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
37. Supplementary Table 2 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
38. Supplementary Figure 1 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas
39. Abstract P3-07-06: Comedications at Breast Cancer diagnosis impact overall survival: results from the ADRENALINE (Atlas for DRug and brEast caNcer survivAL INtEraction) study (n=235,368)
40. A Regression Survival Model for Testing the Proportional Hazards Hypothesis
41. Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)
42. Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study
43. Cancer Risk in Women Exposed to Diethylstilbestrol in Utero
44. O025/#522 Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a parp inhibitor: patient-reported outcomes from the phase IIIB OReO/engot-ov38 trial
45. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies
46. 2022-RA-1290-ESGO Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a PARP inhibitor: detailed safety results from the Phase IIIb OReO/ENGOT-ov38 trial
47. 2022-RA-944-ESGO Real-world safety, baseline characteristics and first-year therapy management in patients withBRCA1/BRCA2-mutated advanced ovarian cancer treated with olaparib tablets in the first-line maintenance setting: first analysis of the pan-European OVAL-1 study
48. 2022-RA-922-ESGO Histo-molecular characteristics of platinum-sensitive advanced endometrial cancer: data issued from the population included in the GINECO UTOLA study
49. Estimation du risque individuel de cancer du sein : intérêt et limites des modèles de calcul de risque
50. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.